Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


23.12.2018

1 Am J Clin Pathol
2 Biochem Biophys Res Commun
1 Biochem Pharmacol
1 Blood
1 Cancer
1 Cancer Res
1 J Pediatr Hematol Oncol
6 Leuk Lymphoma
2 Leuk Res
8 Leukemia
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Pathol

  1. HWANG SM, Park HS, Park S, Kim SM, et al
    Application of Fluorescence In Situ Hybridization on Cerebrospinal Fluid Cytospins for the Detection of Residual Leukemic Cells in Patients With Childhood Acute Lymphoblastic Leukemia.
    Am J Clin Pathol. 2018 Dec 17. pii: 5250888. doi: 10.1093.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  2. DING Y, Xu H, Li L, Yuan Y, et al
    Megakaryocytic leukemia 1 (MKL1) mediates high glucose induced epithelial-mesenchymal transition by activating LOX transcription.
    Biochem Biophys Res Commun. 2018 Dec 13. pii: S0006-291X(18)32667.
    PubMed     Text format     Abstract available

  3. ZHANG W, Sun S, Zhang W, Shi Z, et al
    Polymorphisms of ABCG2 and its impact on clinical relevance.
    Biochem Biophys Res Commun. 2018;503:408-413.
    PubMed     Text format     Abstract available


    Biochem Pharmacol

  4. SU Y, Li X, Ma J, Zhao J, et al
    Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.
    Biochem Pharmacol. 2018;148:13-26.
    PubMed     Text format     Abstract available


    Blood

  5. SCHLENK RF, Weber D, Fiedler W, Salih HR, et al
    Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
    Blood. 2018 Dec 18. pii: blood-2018-08-869453. doi: 10.1182/blood-2018-08-869453
    PubMed     Text format     Abstract available


    Cancer

  6. CHIARETTI S, Messina M, Foa R
    BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31848.
    PubMed     Text format     Abstract available


    Cancer Res

  7. TAKAM KAMGA P, Dal Collo G, Midolo M, Adamo A, et al
    Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-1617.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  8. AMIN ASNAFI A, Bagheri M, Zibara K, Maleki Behzad M, et al
    Expression and Activity of Matrix Metalloproteinases in Leukemia.
    J Pediatr Hematol Oncol. 2018 Dec 14. doi: 10.1097/MPH.0000000000001386.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  9. LAD D, Hoeppli R, Huang Q, Garcia R, et al
    Regulatory T-cells drive immune dysfunction in CLL.
    Leuk Lymphoma. 2018;59:486-489.
    PubMed     Text format    

  10. DANIELZIK T, Koldehoff M, Buttkereit U, Beelen DW, et al
    Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay.
    Leuk Lymphoma. 2018;59:490-492.
    PubMed     Text format    

  11. KASHOFER K, Gornicec M, Lind K, Caraffini V, et al
    Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.
    Leuk Lymphoma. 2018;59:501-504.
    PubMed     Text format    

  12. BEZERRA ED, Smith H, Estey E
    A case of indolent AML with five-year survival without treatment.
    Leuk Lymphoma. 2018;59:519.
    PubMed     Text format    

  13. TANG CPS, McMullen J, Tam C
    Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Leuk Lymphoma. 2018;59:1554-1564.
    PubMed     Text format     Abstract available

  14. SAGLIO G, Jabbour E
    First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
    Leuk Lymphoma. 2018;59:1523-1538.
    PubMed     Text format     Abstract available


    Leuk Res

  15. BROOIMANS RA, van der Velden VHJ, Boeckx N, Slomp J, et al
    Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Leuk Res. 2018;76:39-47.
    PubMed     Text format     Abstract available

  16. KIM HS, Han E, Jang W, Kim M, et al
    Germline CEBPA mutations in Korean patients with acute myeloid leukemia.
    Leuk Res. 2018 Dec 11. pii: S0145-2126(18)30490.
    PubMed     Text format    


    Leukemia

  17. MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
    Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 14. pii: 10.1038/s41375-018-0307.
    PubMed     Text format     Abstract available

  18. TEN HACKEN E, Gounari M, Ghia P, Burger JA, et al
    The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0303.
    PubMed     Text format     Abstract available

  19. PARK JH, Woo YM, Youm EM, Hamad N, et al
    HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0321.
    PubMed     Text format     Abstract available

  20. CORTES JE, Heidel FH, Hellmann A, Fiedler W, et al
    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0312.
    PubMed     Text format     Abstract available

  21. HASAN MK, Rassenti L, Widhopf GF 2nd, Yu J, et al
    Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0306.
    PubMed     Text format     Abstract available

  22. REEDIJK AMJ, Klein K, Coebergh JWW, Kremer LC, et al
    Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0314.
    PubMed     Text format     Abstract available

  23. KIVIOJA JL, Thanasopoulou A, Kumar A, Kontro M, et al
    Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0327.
    PubMed     Text format     Abstract available

  24. VON TRESCKOW J, Cramer P, Bahlo J, Robrecht S, et al
    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0313.
    PubMed     Text format     Abstract available


    PLoS One

  25. SCHUBERT M, Hackl H, Gassner FJ, Greil R, et al
    Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia.
    PLoS One. 2018;13:e0208753.
    PubMed     Text format     Abstract available

  26. KUZELOVA K, Brodska B, Schetelig J, Rollig C, et al
    Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.
    PLoS One. 2018;13:e0204290.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: